L 691121

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 559147

CAS#: 136075-61-1

Description: L 691121 is a bioactive chemical.

Chemical Structure

img
L 691121
CAS# 136075-61-1
Instruction

Theoretical Analysis

MedKoo Cat#: 559147
Name: L 691121
CAS#: 136075-61-1
Chemical Formula: C22H24N4O5S
Exact Mass: 456.15
Molecular Weight: 456.517
Elemental Analysis: C, 57.88; H, 5.30; N, 12.27; O, 17.52; S, 7.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 691121; L-691121; L691121

IUPAC/Chemical Name: Methanesulfonamide, N-(1'-(2-(2,1,3-benzoxadiazol-5-yl)ethyl)-3,4-dihydro-4-oxospiro(2H-1-benzopyran-2,4'-piperidin)-6-yl)-

InChi Key: UISIMLLBTGLBND-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H24N4O5S/c1-32(28,29)25-16-3-5-21-17(13-16)20(27)14-22(30-21)7-10-26(11-8-22)9-6-15-2-4-18-19(12-15)24-31-23-18/h2-5,12-13,25H,6-11,14H2,1H3

SMILES Code: CS(=O)(NC1=CC=C2C(C(CC3(CCN(CCC4=CC5=NON=C5C=C4)CC3)O2)=O)=C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 456.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lynch JJ Jr, Wallace AA, Van der Gaag LH, Baskin EP, Bear CM, Gehret JR, Kothstein T, Stupienski RF, Appleby SD, Sanguinetti MC, et al. Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agent. J Pharmacol Exp Ther. 1993 May;265(2):720-30. PMID: 8496818.


2: Elliott JM, Selnick HG, Claremon DA, Baldwin JJ, Buhrow SA, Butcher JW, Habecker CN, King SW, Lynch JJ Jr, Phillips BT, et al. 4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121). J Med Chem. 1992 Oct 16;35(21):3973-6. doi: 10.1021/jm00099a028. PMID: 1433205.


3: Greber TF, Olah TV, Gilbert JD, Porras AG, Hichens M. Determination of L-691,121, a new class III antiarrhythmic, and its principal metabolite in plasma by differential radioimmunoassay. J Pharm Biomed Anal. 1994 Apr;12(4):483-92. doi: 10.1016/0731-7085(94)80029-4. PMID: 7918764.


4: Zaniboni M, Pollard AE, Yang L, Spitzer KW. Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. Am J Physiol Heart Circ Physiol. 2000 Mar;278(3):H677-87. doi: 10.1152/ajpheart.2000.278.3.H677. PMID: 10710334.


5: Ban Y, Konishi R, Kawana K, Nakatsuka T, Fujii T, Manson JM. Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol. 1994;69(1):65-71. doi: 10.1007/s002040050139. PMID: 7717857.


6: Vickers S, Duncan CA, Kari PH, Homnick CF, Elliott JM, Pitzenberger SM, Hichens M, Vyas KP. In vivo and in vitro metabolism studies on a class III antiarrhythmic agent. Drug Metab Dispos. 1993 May-Jun;21(3):467-73. PMID: 8100503.